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Dr Michael Mack (Dallas, Tex). My disclosure is that I am on
the Executive Committee of the PARTNER Trial of the Edwards
Sapien valve in the United States.
Dr Bleiziffer and the team from Munich have presented their re-
sults in just over 200 patients undergoing TAVI, with approxi-
mately 75% of the procedures being performed by a transfemoral
and 25% by a transapical approach. Their analysis compares two
different access approaches and concludes that transapical out-
comes are adversely affected by patient selection factors such as fe-
male gender, peripheral vascular disease, cerebrovascular disease,
and coronary artery disease. Although I substantially agree with
this assessment, the analysis is somewhat confounded by the fact
that two different valve systems were used: the CoreValve primar-
ily but not exclusively for the transfemoral approach and the Ed-
wards valve primarily but not exclusively for the transapical
approach. I am also concerned that this was not an intent-to-treat
analysis and at least 3 patients with aborted procedures or conver-
sions were not included in the analysis.
Dr Bleiziffer, I would like to highlight some key points of your
series and ask 3 questions.
First, the 30-day survival was approximately the same in both
access approaches, at about 90%, yet the 6-month survival is
only 80% after transfemoral and 73% after transapical. What hap-
pened to these patients between 30 days and 6 months, especially
the transapical patients? Is this a patient selection issue or a com-
ment on the invasive nature of the procedure? I would have ex-
pected the survival curves to be relatively flat after 30 days, but
they do not flatten out until 6 months.
Dr Bleiziffer.As I mentioned, most of the patients died within 3
months and all deaths were indeed related to the procedure. They
had a long intensive care unit stay and died of sequelae of the pro-
cedure. The fact that the transapical curve goes down a little more is
explained because some deaths occurred right in the beginning
among our transapical group.
Dr Mack. Second, the stroke rate is of some concern, being 7%
in the transfemoral and zero in the transapical group. As Dr Bavaria
showed at the Adult Cardiac Postgraduate Course yesterday, in
a small group of patients undergoing the transfemoral approach
with the Edwards system, transcranial Doppler high-intensity tran-
sient signals indicating cerebral emboli occur most frequently with
the passage of the valve across the arch, second with traverse of theThe Journal of Thoracic and Carwire across the arch, and least with valve deployment and balloon
valvuloplasty. Do you therefore consider atherosclerotic disease of
the aortic arch and the ascending aorta yet another ‘‘access issue,’’
and how do you screen for it before deciding on the approach?
Does everybody get a computed tomographic scan to assess the
arch?
Dr Bleiziffer. Every single patient undergoes a computed tomo-
graphic scan of the thorax, abdomen, and pelvis for identification of
the calcifications and anatomy of the root and of the peripheral ves-
sels. At present, the type of calcifications in the arch does not influ-
ence our decision for a transfemoral or a transapical implantation.
And not all of the neurologic events were embolic. Some were in-
tracerebral bleedings. These might not be related to the passage of
the aortic arch.
Dr Mack.My third question relates to the transfemoral-first ap-
proach that you use, as do most programs. With roughly equivalent
results between the two approaches, with the results for stroke bet-
ter with the transapical approach, and with your study showing that
the transapical approach was disadvantaged by patient selection,
why don’t you adopt a transapical-first approach like programs in
Leipzig and Laval? At the minimum, it seems to me, you have
the basis for an all-comer randomized trial between the two ap-
proaches.
Dr Bleiziffer. I did not really understand the question. Could
you repeat it?
Dr Mack. Your approach is a transfemoral-first approach.
Dr Bleiziffer. Yes.
Dr Mack. The outcomes appear to be the same, yet there seems
to be an advantage for transapical from a stroke standpoint. Why
not do a transapical approach first and then the transfemoral in those
in whom transapical is contraindicated, such as severe chronic lung
disease, or why not randomize between the two approaches?
Dr Bleiziffer.Our decision tree is evolving and will develop de-
pending on our long-term results. We confirm our data and adjust
the decision tree at some intervals.
Dr Mack. My suggestion is that you have enough data now to
reassess that decision tree.
Dr Bleiziffer.We do not know about the long-term sequelae of
the apical approach, as I mentioned before, so there are advantages
and disadvantages of both approaches.
Dr Mack. This seem like a perfect time for a randomized trial.
Dr Joseph E. Bavaria (Philadelphia, Pa). I want to congratu-
late this group on being one of the pre-eminent surgical groups in
the world doing transcatheter valve procedures. They are a surgical
group that uses both transfemoral and transapical approaches and
actually uses any appropriate access, such as transsubclavian, tran-
siliac, transaortic, whatever. This allows them to be completely free
of conflict of interest. It is a fantastic group.
I would also like to confirm what Michael Mack just said about
the concept of the transapical-first selection tree as opposed to the
transfemoral-first selection tree. That might be very interesting. I
know there are many groups in Europe that are doing that.
My questions really relate to your learning curve issues. If you
were to take out the first 10 patients on your transfemoral side
and the first 10 patients on your transapical side, where do you think
the curves would go?
Dr Bleiziffer. I did not try that, but I do not think that it would
make much difference now with the larger patient numbers.diovascular Surgery c Volume 138, Number 5 1079
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and the first 10 patients from transfemoral and looked at those
curves, do you think they would be basically the same as you
have up there?
Dr Bleiziffer. I think so, yes.
Dr Bavaria. The second question has to do with your apical
purse strings. There is a debate about whether box techniques ver-
sus purse-string techniques at the apex are the best. Which tech-
nique do you use for your apical suturing?
DrBleiziffer.Weuse twopledget-supported purse-string sutures.
Dr Khalid Rasheed (Islamabad, Pakistan). I congratulate you
on this very elegant presentation regarding a challenging frontier.
Regarding the potential complications of the transapical route,1080 The Journal of Thoracic and Cardiovascular Suryou have mentioned that there is an increased incidence of cardiac
depression requiring various means of cardiopulmonary resuscita-
tion and, second, the chance of producing an apical tear while clos-
ing the entry site. Inasmuch as the second complication is
potentially fatal, what contingency arrangements do you have in
place to deal with this catastrophic complication? Do you routinely
prepare the femoral vessels to enable you to go on cardiopulmonary
bypass to salvage the patient?
Dr Bleiziffer.We routinely place guide wires in the femoral ar-
tery and vein to facilitate the potential extracorporeal bypass instal-
lation.
Dr Rasheed. It is therefore an essential part of the protocol.
Dr Bleiziffer. Yes, in all patients.gery c November 2009
